SCHEDULE: Two Seas Capital Reports 9.1% Stake in Nektar Therapeutics

Investment firm Two Seas Capital LP, along with its GP and CIO Sina Toussi, has disclosed beneficial ownership of 3,092,234 shares, representing 9.1% of Nektar Therapeutics' common stock as of June 30, 2026.

Summary

• Two Seas Capital LP, its general partner Two Seas Capital GP LLC, and its Chief Investment Officer Sina Toussi have filed a Schedule 13G, indicating their beneficial ownership of 3,092,234 shares of Nektar Therapeutics' common stock.
• This ownership stake represents 9.1% of the total outstanding common stock as of June 30, 2026.
• The shares are held through two funds: Two Seas Global (Master) Fund LP and Two Seas Litigation Opportunities Fund LLC.
• Two Seas Capital LP acts as the investment adviser to these funds and has sole voting and dispositive power over the shares.
• Two Seas Capital GP LLC, as the general partner of TSC, and Sina Toussi, as the managing member of TSC GP and CIO of TSC, also hold these powers.
• The filing is an amendment, indicating a change in reporting status or ownership level.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not dominant ownership stake by an investment entity, with no immediate indication of aggressive action or negative developments.

Positives

• Disclosure of a significant ownership stake (9.1%) by an investment entity can signal confidence in the company's future prospects.
• The reporting persons are registered investment advisers, suggesting a professional and strategic approach to their investment.
• The filing is a Schedule 13G, which is typically used by passive investors, implying no immediate intent to control or influence the issuer's management.

Negatives

• A 9.1% stake, while significant, does not grant outright control and could be subject to market fluctuations.
• The filing does not provide specific details on the investment strategy or reasons for acquiring the stake beyond standard disclosures.

Risks

• The investment is subject to market risks inherent in the biotechnology and pharmaceutical sectors.
• Changes in Nektar Therapeutics' clinical trial progress, regulatory approvals, or financial performance could negatively impact the value of the investment.
• Potential for future changes in ownership or strategy by Two Seas Capital LP.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from Nektar Therapeutics. The future outlook for the investment depends on the company's performance and market conditions.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Nektar Therapeutics operates in the highly competitive and research-intensive biotechnology sector. Significant ownership stakes by investment firms can sometimes precede activist campaigns or strategic shifts, though this filing suggests a passive investment posture.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment firm may influence investor sentiment and trading activity.
• Management: The company's management will be aware of the substantial ownership by Two Seas Capital LP.
• Creditors: No direct impact indicated, but overall company performance affects creditworthiness.

Next Steps

• Continued monitoring of Nektar Therapeutics' operational and financial performance.
• Observation of any future filings or announcements from Two Seas Capital LP regarding their stake.
• Tracking Nektar Therapeutics' progress in its drug development pipeline and regulatory milestones.

Key Dates

Keywords

Nektar Therapeutics, Schedule 13G, Two Seas Capital LP, Investment Adviser, Beneficial Ownership, Common Stock, Sina Toussi, Biotechnology